The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: An effect influenced by testosterone

Prostate

Volumn 69, Issue 11, 2009, Pages 1164-1175

  Jennbacken, Karin ^a   Gustavsson, Heléne ^a   Tešan, Tajana ^a   Horn, Michael ^a   Vallbo, Christina ^a   Welén, Karin ^a   Damber, Jan Erik ^a  

^a SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Hormone refractory; LNCaP; Magnetic resonance imaging; Microarray; Orthotopic implantation; Prostate carcinoma

Indexed keywords

NERVE CELL ADHESION MOLECULE; RGS2 PROTEIN; TESTOSTERONE; ADAM PROTEIN; ADAMTS1 PROTEIN, HUMAN; ANDROGEN; CADHERIN; CELL ADHESION MOLECULE; NRCAM PROTEIN, HUMAN; RGS PROTEIN; RGS2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CASTRATION; CELL ADHESION; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MICROARRAY ANALYSIS; MICROENVIRONMENT; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; SUBCUTANEOUS TISSUE; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG EFFECT; METABOLISM; NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

ADAM PROTEINS; ADENOCARCINOMA; ANDROGENS; ANIMALS; CADHERINS; CASTRATION; CELL ADHESION; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATE; PROSTATIC NEOPLASMS; RGS PROTEINS; TESTOSTERONE; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 67650594744     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20965     Document Type: Article

References (36)

1. Damber JE, Aus G. Prostate cancer. Lancet 2008;371(9625):1710-1721.
2. Monsky WL, Mouta Carreira C, Tsuzuki Y, Gohongi T, Fukumura D, Jain RK. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: Mammary fat pad versus cranial tumors. Clin Cancer Res 2002;8(4):1008-1013.
3. Van Hoorde L, Pocard M, Maryns I, Poupon MF, Mareel M. Induction of invasion in vivo of alpha-catenin-positive HCT-8 human colon-cancer cells. Int J Cancer 2000;88(5):751-758.
4. Nakajima M, Morikawa K, Fabra A, Bucana CD, Fidler IJ. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst 1990;82(24):1890-1898.
5. Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, Fidler IJ. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992;84(12):951-957.
6. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003;107(1):1-10.
7. Ohlson N, Bergh A, Stattin P, Wikstrom P. Castration-induced epithelial cell death in human prostate tissue is related to locally reduced IGF-1 levels. Prostate 2007;67(1):32-40.
8. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocker H. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996;28(6):392-405.
9. Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, Hayward SW, Cunha GR, Marker PC. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res 2005;65(22):10423-10430.
10. Gustavsson H, Welen K, Damber JE. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 2005;62(4):364-373.
11. Jennbacken K, Gustavsson H, Welen K, Vallbo C, Damber JE. Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity. Prostate 2006;66(15):1631-1640.
12. Gareis D, Wichmann T, Lanz T, Melkus G, Horn M, Jakob PM. Mouse MRI using phased-array coils. NMR Biomed 2007;20(3):326-334.
13. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4(2):249-264.
14. Tesan T, Gustavsson H, Welen K, Damber JE. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models. BJU Int 2008;102(8):1034-1039.
15. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 2001;61(22):8135-8142.
16. Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M, Burnstein KL, Nanus DM. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology 2000;141(5):1699-1704.
17. Chuu CP, Hiipakka RA, Kokontis JM, Fukuchi J, Chen RY, Liao S. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res 2006;66(13):6482-6486.
18. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LW. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 1996;93(26):15152-15157.
19. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998;12(7):941-953.
20. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34(7):646-653.
21. Ohlson N, Bergh A, Nygren K, Stattin P, Wikstrom P. The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome. Eur Urol 2006;49(4):675-683.
22. Kanai M, Ishii K, Kanda H, Ogura Y, Kise H, Arima K, Sugimura Y. Improvement in predicting tumorigenic phenotype of androgen-insensitive human LNCaP prostatic cancer cell subline in recombination with rat urogenital sinus mesenchyme. Cancer Sci 2008;99(12):2435-2443.
23. Wikstrom P, Lindahl C, Bergh A. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy. Prostate 2005;62(2):148-164.
24. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54(10):2577-2581.
25. Gustavsson H, Jennbacken K, Welen K, Damber JE. Altered expression of genes regulating angiogenesis in experimental androgen-independent prostate cancer. Prostate 2008;68(2):161-170.
26. Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, Iruela-Arispe ML. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 1999;274(33):23349-23357.
27. Masui T, Hosotani R, Tsuji S, Miyamoto Y, Yasuda S, Ida J, Nakajima S, Kawaguchi M, Kobayashi H, Koizumi M, Toyoda E, Tulachan S, Arii S, Doi R, Imamura M. Expression of METH-1 and METH-2 in pancreatic cancer. Clin Cancer Res 2001;7(11):3437-3443.
28. Imoto I, Izumi H, Yokoi S, Hosoda H, Shibata T, Hosoda F, Ohki M, Hirohashi S, Inazawa J. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res 2006;66(9):4617-4626.
29. Cao X, Qin J, Xie Y, Khan O, Dowd F, Scofield M, Lin MF, Tu Y. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene 2006;25(26):3719-3734.
30. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007;13(23):7003-7011.
31. Tran NL, Nagle RB, Cress AE, Heimark RL. N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with stromal cells. Am J Pathol 1999;155(3):787-798.
32. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ, Schalken JA. Cadherin switching in human prostate cancer progression. Cancer Res 2000;60(13):3650-3654.
33. Conacci-Sorrell M, Kaplan A, Raveh S, Gavert N, Sakurai T, Ben-Ze'ev A. The shed ectodomain of Nr-CAM stimulates cell proliferation and motility, and confers cell transformation. Cancer Res 2005;65(24):11605-11612.
34. Gorka B, Skubis-Zegadlo J, Mikula M, Bardadin K, Paliczka E, Czarnocka B. NrCAM, a neuronal system cell-adhesion molecule, is induced in papillary thyroid carcinomas. Br J Cancer 2007;97(4):531-538.
35. Conacci-Sorrell ME, Ben-Yedidia T, Shtutman M, Feinstein E, Einat P, Ben-Ze'ev A. Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev 2002;16(16):2058-2072.
36. Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, Blute ML. Metastatic prostate carcinoma to bone: Clinical and pathologic features associated with cancer-specific survival. Cancer 2002;95(5):1028-1036.